Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.
Zhukova. G V GV; Schikhlyarova. A I AI; Barteneva. T A TA; Shevchenko. A N AN; Zakharyuta. F M FM
Key Findings
- Low‑dose Thymalin halted tumor growth and caused regression in >50% of rats with transplanted sarcoma.
- Tumor growth was suppressed by up to 78% in the remaining animals.
- Thymus showed increased lymphocyte proliferation and more basophils and plasmocytes, indicating enhanced immune activity.
Practical Outcomes
- The study suggests that very low doses of Thymalin might have anti‑cancer and immune‑boosting effects, especially when the dosing schedule is adjusted over time. However, the data are from an animal model only, so there’s no direct guidance for human use yet. Biohackers should view this as early‑stage evidence and wait for human trials before incorporating Thymalin into longevity or performance protocols.
Summary
In a rat study, the peptide Thymalin given at doses lower than typical therapeutic levels slowed down or even shrank tumors in more than half of the animals. It also boosted activity in the thymus, a key immune organ, and seemed to help the animals stay calm and less stressed. The researchers think the good results come from using low doses and adjusting them over time.
Abstract
Pronounced antitumor effect of Thymalin in doses lower than the therapeutic doses was shown in experiments on albino outbred male rats with transplanted sarcoma 45. Tumor growth arrest and its regression were observed in more than half of animals and in other cases, the growth was suppressed by 78%. Microstructural changes in the thymus were analyzed. Significant increase in lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymus lobules was observed. Tumor regression was accompanied by the development of stable antistress adaptation reactions of calm and elevated activation. High efficiency of Thymalin can be attributed to the use of lower doses of the substance and their modulation during the treatment course in accordance with the regimes of activation therapy.
Study Information
pubmed
2018
2018-05-24T00:00:00.000Z
10.1007/s10517-018-4104-z
9
16